Calliditas Therapeutics AB (Calliditas Therapeutics AB) Common Stock : $0.23 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Common Stock?

Calliditas Therapeutics AB's quarterly common stock stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.23 Mil).

Calliditas Therapeutics AB's annual common stock stayed the same from Dec. 2021 ($0.23 Mil) to Dec. 2022 ($0.23 Mil) but then increased from Dec. 2022 ($0.23 Mil) to Dec. 2023 ($0.23 Mil).

Calliditas Therapeutics AB Common Stock Historical Data

The historical data trend for Calliditas Therapeutics AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Common Stock Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.16

0.24

0.23

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															0.22	0.23	-	-	0.23

Calliditas Therapeutics AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.